Abstract:Abstract Constitutive activation of Signal Transducers and Activators of Transcription 3 (STAT3) signaling is frequently detected in human cancer, including breast cancer, and has emerged as a viable molecular target for breast cancer treatment. Novel therapeutic approaches are needed for breast cancer if significant improvements in survival are to occur. To date, few STAT3 inhibitors are available for the therapy of breast cancer. Conventional high throughput screening and virtual docking drug discovery approaches identified many hits, but only a few of them may be developed into drugs. To accelerate STAT3 drug development, we used a novel drug discovery approach with multiple ligand simultaneous docking (MLSD) which we have developed and drug repositioning to search against FDA approved drug and experimental drug database in DrugBank. Using this new method, we identified the FDA-approved drug celecoxib (a COX-2 inhibitor) with a novel function to target STAT3 [Predictive STAT3 binding dissociation constant (Kd)= 8.6 μM]. In addition, a novel celecoxib analog (8A) was developed exhibiting stronger STAT3 binding (Predicted Kd= 0.12 μM, 71-fold stronger than celecoxib). Although 8A has stronger STAT3 binding, it has weaker COX-2 binding (521-fold weaker than celecoxib), suggesting its selectivity on STAT3 versus COX-2. Minimal COX-2 inhibition by 8A may reduce cardiovascular and gastrointestinal risks associated with COX-2 inhibitors. The ability of 8A to inhibit STAT3 was tested through a combination of Western Blot, MTT cell viability assay, and Immunofluorescence Standing. 8A inhibited the P-STAT3 stimulated by IL-6 but not the induction of STAT1, STAT2, STAT4, STAT5, and STAT6 phosphorylation stimulated by IFN-γ, IFN-γ, and IL-4. 8A also inhibited the induction of STAT3 nuclear localization by IL-6, which could prevent STAT3 function as a transcription factor. 8A inhibited STAT3 phosphorylation and resulted in the induction apoptosis on breast cancer cells as evidenced by caspase-3 cleavage. Further, 8A has a lower IC50 than celecoxib and was more potent than celecoxib to inhibit STAT3 phosphorylation and induce apoptosis in breast cancer cells, which confirmed the stronger STAT3 binding energy than celecoxib. In summary, our study is the first report using MLSD and drug repositioning to develop drug-like STAT3 inhibitors. This novel method has a potential to significantly speed up the STAT3 drug development for the therapy of breast cancer and possibly other types of human cancer which express constitutive STAT3 signaling. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4772. doi:1538-7445.AM2012-4772

The Tetramethylpyrazine Derivative Statmp-151: A Novel Small Molecule Stat3 Inhibitor With Promising Activity Against Breast Cancer

HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Data from HMGN5 Escorts Oncogenic STAT3 Signaling by Regulating the Chromatin Landscape in Breast Cancer Tumorigenesis

Identification of New Shikonin Derivatives As Antitumor Agents Targeting Stat3 Sh2 Domain

Identification of New Shikonin Derivatives As STAT3 Inhibitors.

Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy

A Low-Molecular-weight Compound Discovered Through Virtual Database Screening Inhibits Stat3 Function in Breast Cancer Cells.

Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study

A Novel Sulfonamide Agent, MPSP-001, Exhibits Potent Activity Against Human Cancer Cells in Vitro Through Disruption of Microtubule

Design, synthesis and biological evaluation of novel naphthoquinothiazole derivatives as potent antitumor agents through inhibiting STAT3

Abstract 1659: Development of HJC0152, its analogs and protein degraders to modulate STAT3 for triple-negative breast cancer therapy

Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer

The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts

STAT3: Key targets of growth-promoting receptor positive breast cancer

Discovery of 4-methoxy-N-(1-naphthyl)benzenesulfonamide derivatives as small molecule dual-target inhibitors of tubulin and signal transducer and activator of transcription 3 (STAT3) based on ABT-751

A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion

Small Molecule Induces Time‐Dependent Inhibition Of Stat3 Dimerization And Dna‐Binding Activity And Regresses Human Breast Tumor Xenografts

Abstract 4772: Novel drug discovery approach targeting STAT3 for breast cancer therapy using MLSD and drug repositioning

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking

Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis

Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors